Refine by
Intellia T Cells Equipment & Supplies
1 equipment items found
by:Intellia Therapeutics, Inc. based inCambridge, MASSACHUSETTS (USA)
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia (AML) by engineering autologous T cell receptors (TCR) directed towards the ...